Evaluating the Long-Term Need for Antiparkinson Drugs by Chronic Schizophrenics

摘要: Chronic schizophrenic males receiving both antipsychotic and antiparkinson medication had the latter replaced by placebo for a sixweek study period. To provide double-blind control, smaller group received matching tablets of benztropine mesylate. Of 403 patients placebos, 7% were withdrawn from because substantial return or appearance extrapyramidal symptoms. Another 11% judged to be worse rating scale data, but remaining 82% seemed get along quite well without medication, experiencing at most some temporary symptoms system disturbance. From these other it is recommended that clinicians reconsider their prescribing habits, particularly prophylactic long-term use drugs.